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A B S T R A C T
Objectives: This study was designed to propose a simple “Fast Track algorithm” for capillaroscopists of any level
of experience to differentiate “scleroderma patterns” from “non-scleroderma patterns” on capillaroscopy and to
assess its inter-rater reliability.
Methods: Based on existing definitions to categorise capillaroscopic images as “scleroderma patterns” and taking
into account the real life variability of capillaroscopic images described standardly according to the European
League Against Rheumatism (EULAR) Study Group on Microcirculation in Rheumatic Diseases, a fast track
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decision tree, the “Fast Track algorithm” was created by the principal expert (VS) to facilitate swift categor-
isation of an image as “non-scleroderma pattern (category 1)” or “scleroderma pattern (category 2)”. Mean inter-
rater reliability between all raters (experts/attendees) of the 8th EULAR course on capillaroscopy in Rheumatic
Diseases (Genoa, 2018) and, as external validation, of the 8th European Scleroderma Trials and Research group
(EUSTAR) course on systemic sclerosis (SSc) (Nijmegen, 2019) versus the principal expert, as well as reliability
between the rater pairs themselves was assessed by mean Cohen's and Light's kappa coefficients.
Results: Mean Cohen's kappa was 1/0.96 (95% CI 0.95–0.98) for the 6 experts/135 attendees of the 8th EULAR
capillaroscopy course and 1/0.94 (95% CI 0.92–0.96) for the 3 experts/85 attendees of the 8th EUSTAR SSc
course. Light's kappa was 1/0.92 at the 8th EULAR capillaroscopy course, and 1/0.87 at the 8th EUSTAR SSc
course.
Conclusion: For the first time, a clinical expert based fast track decision algorithm has been developed to dif-
ferentiate a “non-scleroderma” from a “scleroderma pattern” on capillaroscopic images, demonstrating excellent
reliability when applied by capillaroscopists with varying levels of expertise versus the principal expert and
corroborated with external validation.
1. Introduction
The “scleroderma pattern” on capillaroscopy has been incorporated
into the 2013 American College of Rheumatology (ACR)/ European
League Against Rheumatism (EULAR) classification criteria, as well as
in criteria to facilitate a (very) early diagnosis of systemic sclerosis
(SSc) [1–3]. Its importance is based on the fact that the combination of
a “scleroderma pattern” and SSc specific antibodies has the highest
performance characteristics to discern in a Raynaud's phenomenon
population who will and who will not develop SSc [4].
In 1973 and more detailed in 1981, Maricq et al. was the first to
describe key capillary abnormalities of a “scleroderma pattern” using
“wide-field” capillary microscopy as “enlargement of capillary loops,
loss of capillaries (‘loop drop-out’), disruption of the normal capillary
architecture and haemorrhages” [5,6]. Moreover, in her seminal
quantitative study she measured with the stereomicroscopic technique
the apical diameter of “definitely enlarged” capillaries, and found a
mean apical diameter of 47.7 μm ± 5.8 to be specific for scleroderma
spectrum diseases [7]. This finding was adopted and further developed
by Cutolo et al. who likewise defined “giant capillaries” with the
Fig. 1. The “Fast Track algorithm”.
The Fast Track algorithm” consists of three easy rules: 1) Rule 1: a capillary density≥ 7 capillaries AND the absence of giant capillaries allows the rater to call the
capillaroscopic image a “non-scleroderma pattern (category 1)”; 2) Rule 2: an extremely lowered capillary density (≤ 3 capillaries) in combination with abnormal
shapes (i.e. “late scleroderma pattern”) OR the presence of giant capillaries allows the capillaroscopist to call the capillaroscopic image “a scleroderma pattern
(category 2)”; 3) Rule 3: if the image does not meet rule number 1 or rule number 2 then the image is automatically classified as a” non-scleroderma pattern
(category 1)”.
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nailfold videocapillaroscopic (NVC) technique as homogeneously en-
larged capillaries with a normal shape and apical diameter over 50 μm
[8]. The presence of these giant capillaries on NVC is interesting, as it
allows distinction between SSc and non-SSc with over 95.6% specificity
[9,10]. Of note, giant capillaries are the hallmark of the “early” and
“active” scleroderma patterns, whilst the “late” scleroderma pattern is
characterised by the combination of severe loss of capillaries combined
with abnormal shapes (“[neo-] angiogenesis”) [7,8].
Even though the classification of a capillaroscopic image as “scler-
oderma pattern” or not has a high inter-rater reliability between trained
capillaroscopists, to the untrained rheumatologist this classification
may be very challenging [11–13]. One of the reasons may be the vast
variety of non-specific abnormalities of capillaroscopic characteristics
(i.e. of capillary density, capillary dimension, capillary morphology and
haemorrhages) that may be found in the general population (see below
and in Supplementary File 1).
To facilitate the non-trained capillaroscopist in easily classifying
an image as “scleroderma pattern” or “non-scleroderma pattern”, the
EULAR Study Group on Microcirculation in Rheumatic Diseases
(EULAR SG MC/RD), a non-profit international network of expert
centres established in 2014 which has as its main (research) focus to
facilitate standardization of different non-invasive techniques,
decided to create a swiftly trainable decision tree, the “Fast Track
algorithm”, based on existing definitions to categorise capillaroscopic
images into the category of “scleroderma patterns” or into the cate-
gory of “non-scleroderma patterns”. Additionally, the EULAR SG MC/
RD decided to assess the reliability of raters using this decision tree to
classify capillaroscopic images. The key advantage of a fastly train-
able, reliable decision tree would be that any capillaroscopist of any
level of experience would be able to use this, knowing that he/she
would rate likewise to a principal capillaroscopy expert, without the
need to evaluate each single capillaroscopic characteristic that can be
evaluated in capillaroscopy for research aims (see below and
Supplementary File 1).
2. Methods
2.1. “Fast Track algorithm”
Based on the standard interpretation of capillaroscopic images by
the EULAR SG MC/RD, more specifically of the following capillaro-
scopic characteristics: capillary density, capillary dimension, presence
of abnormal capillary shapes and presence of haemorrhages (see
Supplementary File 1) and based on the key elements of the “scler-
oderma pattern”, a decision tree (i.e. the “Fast Track algorithm”) was
consented by two founding members of the EULAR SG MC/RD (VS, MC)
(see Fig. 1). The “Fast Track algorithm” consists of three easy rules: 1)
Rule number 1: the presence of ≥7 capillaries (capillary density) AND
the absence of giant capillaries (capillary dimension) allows the rater to
call the capillaroscopic image a “non-scleroderma pattern (category
1)”; 2) Rule number 2: the presence of giant capillaries or the presence
of an extremely lowered capillary density (≤ 3 capillaries) in combi-
nation with abnormal shapes (= “late” scleroderma pattern) allows the
capillaroscopist to call the capillaroscopic image a “scleroderma pattern
(category 2)”; 3) Rule number 3: if the image does not meet rule
number 1 or rule number 2 then the image is automatically classified as
a “non-scleroderma pattern (category 1)” (see Fig. 1).
2.2. Capillaroscopic images
Thirty representative NVC images (i.e. 14 images with “scleroderma
pattern” and 16 with “non-scleroderma pattern”) with good visibility,
Table 1
Mean Cohen's kappa (95% CI) and Light's kappa for the groups of raters at the
8th EULAR course on capillaroscopy in Rheumatic Diseases (Genoa 2018).
Group of raters Mean Cohen's kappa (95%
CI)
Light's kappa
Expert raters (n=6) 1 1
Attendees (n= 135) 0.96 (0.95–0.98) 0.92
“Novices” (n= 68) 0.98 (0.96–0.99) 0.95
“Moderately experienced”
(n= 53)
0.96 (0.93–0.99) 0.91
“Experienced” (n= 14) 0.93 (0.85–1) 0.84
CI: Confidence Interval.
Fig. 2. Examination setting.
After the teaching lecture, the PowerPoint slide of the “Fast Track algorithm” was projected in the room during the whole examination (A) and the attendees had the
picture of the “Fast Track algorithm” at hand during the examination (B).
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acquired by an optical probe videocapillaroscope equipped with a
200× magnification contact lens, were randomly selected from all NVC
examinations of patients referred to the Ghent University Scleroderma
Unit between December 2017 and June 2018 (see Supplementary File 2
for the examination set with all capillaroscopic images). In the distal
row, the apical diameter of dilated capillaries was reported by a trainee
(MG), who had been trained by the principal expert (VS). All images
were proofread by the principal expert (VS). Categorisation of images as
“scleroderma pattern” or “non-scleroderma pattern” had been executed
by the principal expert (VS).
2.3. Procedure of teaching the “Fast Track algorithm” and examining the
raters
In the first part of this international multicentre study, a 45min
lasting lecture (“Capillaroscopy in daily practice”) was given at the 8th
EULAR course on capillaroscopy in Rheumatic Diseases in Genoa
(September 2018) to 141 attendees, more specifically 6 experts in ca-
pillaroscopy and 135 attendees with varying levels of experience in
capillaroscopy: 68 “novices”, 53 “moderately experienced” and 14
“experienced” (see Table 1). In this lecture the EULAR SG MC/RD
standardly assessed capillaroscopic characteristics (capillary density,
capillary dimension, abnormal morphology and haemorrhages) were
explained step by step by the principal expert (VS) and for the atten-
dees' information an overview of all possible combinations of each of
the capillaroscopic characteristics resulting into either “scleroderma
patterns” or oppositely “non-scleroderma patterns” was taught both
theoretically and applied to exemplary images (see Supplementary File
1 and 3). The “Fast Track algorithm” was applied to each capillaro-
scopic image and explained by the teacher, the principal expert (VS).
Hence, in this interactive way, the audience was stimulated to actively
learn the “Fast Track algorithm” (see Fig. 1). After the teaching lecture,
the attendees had the picture of the “Fast Track algorithm” at hand
during the examination (see Fig. 1). In addition, the PowerPoint slide of
the “Fast Track algorithm” had also been projected in the room during
the whole examination (see Fig. 2A and B). The exams existed of 16
pages, containing two capillaroscopic images per page (see Supple-
mentary File 2). Next to an image the attendee was asked to choose
between two options by applying a cross, i.e. more specifically category
1 (“non-scleroderma pattern”) or category 2 (“scleroderma pattern”)
(see Supplementary File 2). Collaboration between attendees to execute
the exam was not allowed. Two trainees (AV, MG) of the principal
expert (VS) as well as the principal expert (VS) and the senior author
(MC) supervised the room to avoid any collaboration between attendees
in taking the exam. Of note, the raters (experts and attendees) were
asked to attest their levels of expertise in capillaroscopy into one of the
following categories: “novices” (no experience), “moderately experi-
enced” (< 5 years of experience with capillaroscopy) and “experi-
enced” raters (> 5 years of experience with capillaroscopy).
In a second time, as an external validation, this procedure was re-
peated during the 8th European Scleroderma Trials and Research group
(EUSTAR) course on SSc in Nijmegen (February 2019) on 88 attendees,
more specifically 3 experts and 85 attendees with varying levels of
knowledge of capillaroscopy: 47 “novices”, 29 “moderately experi-
enced” and 9 “experienced” (see Table 2).
2.4. Statistical analysis
Inter-rater agreement for each rater versus the principal expert (VS),
i.e. “mean index of reliability”, was calculated for the group of experts,
“novices”, “moderately experienced” raters and “experienced” raters,
both at the 8th EULAR course on capillaroscopy in Rheumatic Diseases
and for reasons of external validation, as well at the 8th EUSTAR course
on SSc. To this end, the mean Cohen's kappa value was reported, which
is estimated by taking the mean of all Cohen's kappa statistic scores
between raters and the principal expert (VS) (see Fig. 3A) [14].
Additionally, the agreement between all possible rater pairs, irre-
spective of the principal expert (VS), was reflected through reporting
the Light's kappa. Hence, conceivably, if the algorithms should be re-
presentative for the experts (other than the principal expert) then the
Light's kappa should be high in between the experts (see Fig. 3B) [14].
Thirdly, to get an idea of the percentage of raters at both courses
which had a nearly perfect agreement, which is a kappa of> 0.8 versus
the principal expert (VS), the distribution of the individual kappa's was
calculated [15].
3. Results
3.1. Raters
Six expert raters (MC, AH, FI, VR, AS, VS [principal expert]) and
135 attendees (68 “novices”, 53 “moderately experienced” and 14
“experienced” raters, from 43 different countries) participated at the
8th EULAR course on capillaroscopy in Rheumatic Diseases and 3 ex-
pert raters (MC, MV, VS [principal expert]) and 85 attendees (47 no-
vices, 29 moderately experienced and 9 experienced raters, from 22
different countries) participated at the 8th EUSTAR course on SSc.
3.2. Inter-rater reliability
The mean index of reliability (i.e. mean Cohen's kappa) based on 30
images was 1 for the expert raters present at the 8th EULAR course on
capillaroscopy in Rheumatic Diseases (n=6) and 1 for the expert raters
present at the 8th EUSTAR course on SSc (n=3). The mean index of
reliability was 0.96 (95% Confidence Interval [CI] 0.95–0.98) for the
attendees of the 8th EULAR course on capillaroscopy in Rheumatic
Diseases (n=135) and 0.94 (95% CI 0.92–0.96) for the attendees of the
8th EUSTAR course on SSc (n=85). Subgroup analysis according to the
level of experience of the attendees, demonstrated a mean Cohen's
kappa of 0.98 (95% CI 0.96–0.99) and 0.93 (95% CI 0.90–0.96) for
“novices” (at the 8th EULAR course on capillaroscopy in Rheumatic
Diseases and 8th EUSTAR course on SSc respectively), 0.96 (95% CI
0.93–0.99) and 0.94 (95% CI 0.89–0.98) for “moderately experienced”
raters (at the 8th EULAR course on capillaroscopy in Rheumatic
Diseases and 8th EUSTAR course on SSc respectively) and 0.93 (95% CI
0.85–1) and 0.97 (95% CI 0.92–1) for “experienced” raters (at the 8th
EULAR course on capillaroscopy in Rheumatic Diseases and 8th
EUSTAR course on SSc respectively).
Inter-rater agreement for each possible combination of rater pairs
(i.e. Light's kappa), irrespective of the principal expert (VS), based on
the 30 images was 1 for the expert raters present at the 8th EULAR
course on capillaroscopy in Rheumatic Diseases (n=6) and 1 for the
expert raters present at the 8th EUSTAR course on SSc (n= 3). The
inter-rater agreement for each possible combination of rater pairs, ir-
respective of the principal expert was 0.92 for the attendees of the 8th
EULAR course on capillaroscopy in Rheumatic Diseases (n= 135) and
0.87 for the attendees of the 8th EUSTAR course on SSc (n=85).
Subgroup analysis demonstrated a Light's kappa of 0.95 and 0.87 for
Table 2
Mean Cohen's kappa (95% CI) and Light's kappa for the groups of raters at the
8th EUSTAR course on SSc (Nijmegen 2019).
Group of raters Mean Cohen's kappa (95%
CI)
Light's kappa
Expert raters (n=3) 1 1
Attendees (n= 85) 0.94 (0.92–0.96) 0.87
“Novices” (n= 47) 0.93 (0.90–0.96) 0.85
“Moderately experienced”
(n=29)
0.94 (0.89–0.98) 0.88
“Experienced” (n=9) 0.97 (0.92–1) 0.94
CI: Confidence Interval.
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“novices” (at the 8th EULAR course on capillaroscopy in Rheumatic
Diseases and 8th EUSTAR course on SSc respectively), 0.91 and 0.88 for
“moderately experienced” raters (at the 8th EULAR course on ca-
pillaroscopy in Rheumatic Diseases and 8th EUSTAR course on SSc
respectively) and 0.84 and 0.94 for “experienced” raters (at the 8th
EULAR course on capillaroscopy in Rheumatic Diseases and 8th
EUSTAR course on SSc respectively).
3.3. Percentage of raters with high agreement versus the principal expert
The distribution of the individual kappa's showed that 95% of raters
at the 8th EULAR course on capillaroscopy in Rheumatic Diseases in
Genoa and 89% of raters at the 8th EUSTAR course on SSc in Nijmegen
had a kappa of> 0.8 versus the principal expert (VS).
4. Discussion
This is the first international multicentre study to step forward to
the need to find an easy rule of thumb decision tree (i.e. the “Fast Track
algorithm”) to categorise capillaroscopic images as “scleroderma pat-
tern” or “non-scleroderma pattern”. A principal expert (VS) had first
classified 30 images, taken with a nailfold videocapillaroscope with a
200× magnification, as “scleroderma pattern” or “non-scleroderma
pattern”, the latter comprising perfectly normal images but also images
with non-specific abnormalities. Then, in two renowned international
training courses (the 8th EULAR course on capillaroscopy in Rheumatic
Diseases and the 8th EUSTAR course on SSc) course raters (experts and
attendees of different level of experience [“novices”, “moderate ex-
perienced”, “experienced”]) had been trained in 45min by the principal
expert to categorise images in the exact same way as the principal ex-
pert through exemplary teaching the “Fast Track algorithm”.
Subsequently, both in the pilot study at the 8th EULAR course on ca-
pillaroscopy in Rheumatic Diseases in Genoa, as well as in the external
validation study at the 8th EUSTAR course on SSc in Nijmegen, an
excellent inter-rater reliability, not only versus the principal expert
rater (mean Cohen's kappa) but also in between the raters themselves
(Light's kappa) was found in categorizing capillaroscopic images as
“scleroderma pattern” or as “non-scleroderma pattern”. Hence, we
strongly feel that this “Fast Track algorithm” may be used safely as a
teaching tool in daily practice to capillaroscopists with any level of
experience, with the aim to have certainty to categorise a capillaro-
scopic image as a “scleroderma pattern” in the same way that an expert
rater does.
This swiftly trainable and reliable decision tree is important, cer-
tainly as the “scleroderma pattern” is a criterion in the new 2013 ACR/
EULAR classification criteria for systemic sclerosis [3]. Correct attri-
bution (vis à vis a principal expert as repère point) of a capillaroscopic
image to the “scleroderma pattern” category is key to correctly denote a
patient to meet the criterion of “abnormal capillaroscopy” of the 2013
ACR/EULAR criteria [3].
One of the advantages of the “Fast Track algorithm” is that only
simple capillaroscopic characteristics were needed to teach the raters,
more specifically, capillaroscopic characteristics that have attested
through literature to have a high inter-rater reliability: “capillary den-
sity” (number of capillaries), “giant capillaries” (capillaries with an
apical diameter≥ 50 μm) and “abnormal shapes” [13,16–24]. Rather
than trying to train the eye of the rater to interpret capillaroscopic
images according to any combination of all existing capillaroscopic
characteristics that are being used nowadays in research which may be
quite challenging to the untrained capillaroscopists (see Supplementary
File 1), with the “Fast Track algorithm” the capillaroscopist only has to
check three rules which automatically lead him/her to a correct cate-
gorisation, more specifically into a “scleroderma pattern or “non-
scleroderma pattern”.
Additionally, we want to draw attention to the fact that the aim of
this study was not to assess discriminatory characteristics of capillaro-
scopy to differentiate between healthy controls, primary Raynaud's
patients and patients with secondary Raynaud's phenomenon due to
SSc. Landmark work on this issue has already been done [4,25,26].
Moreover, such a research question would have needed a totally dif-
ferent statistical approach with calculation of receiver operating curves
and calculation of sensitivity and specificity of capillaroscopy to dis-
criminate healthy controls and primary from secondary Raynaud's
phenomenon due to SSc. In contrast, our intention was to assess an
expert designed decision tree, the “Fast Track algorithm”, with the aim
to enable every capillaroscopist of any level of experience to differ-
entiate within groups of clinically relevant capillaroscopic patterns,
more specifically between “the scleroderma patterns” versus the “non-
scleroderma patterns”.
5. Conclusion
For the first time, a clinical expert based fast track decision algo-
rithm has been developed to differentiate a “non-scleroderma” from a
“scleroderma pattern” on capillaroscopic images. This algorithm de-
monstrated an excellent reliability when applied by capillaroscopists
with varying levels of expertise versus the principal expert, at the 8th
EULAR course on capillaroscopy in Rheumatic Diseases in Genoa and
corroborated with external validation at the 8th EUSTAR course on SSc
in Nijmegen.
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